Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6558986 | 0.83 | ADORA3 (0.32) | ADORA3ADORA1 | |
| SCHEMBL50368 | 0.78 | — | — | |
| SCHEMBL9344255 | 0.78 | — | — | |
| SCHEMBL4853121 | 0.76 | GAA (0.52) | GAAL3MBTL1 | |
| SCHEMBL7941187 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL4960439 | 0.74 | GAA (0.50) | GAAL3MBTL1 | |
| Hydrochloric Acid SCHEMBL4436968 | 0.72 | GAA (0.48) | GAAL3MBTL1 | |
| SCHEMBL9345395 | 0.71 | ADORA3 (0.34) | ADORA3ADORA1 | |
| SCHEMBL632418 | 0.71 | — | — | |
| SCHEMBL14067378 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000455-B2 | Method for treating diseases associated with oxidative stress or endothelial dysfunction using substituted 1-pyrrolidinyloxy, 1-piperidinyloxy and 1-azepanyloxy compounds | Salzman Group, Inc. (US) | 2018-06-19 | — | — | US | disclosed |
| CN-105283181-B | Prodrug of Multifunctional nitroxide derivative and application thereof | 萨尔兹曼集团有限公司 | 2018-04-06 | — | — | CN | disclosed |
| EP-2964218-B1 | PRODRUGS OF MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | RADIKAL THERAPEUTICS INC (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20170327466-A1 | METHOD FOR TREATING DISEASES ASSOCIATED WITH OXIDATIVE STRESS OR ENDOTHELIAL DYSFUNCTION | Salzman Group, Inc. | 2017-11-16 | — | — | US | disclosed |
| US-9604932-B2 | Substituted 1-pyrrolidinyloxy, 1-piperidinyloxy and 1-azepanyloxy compounds for treating diseases associated with oxidative stress or endothelial dysfunction | RADIKAL THERAPEUTICS INC. (US) | 2017-03-28 | — | — | US | disclosed |
| CN-105283181-A | Prodrugs of multifunctional nitroxide derivatives and uses thereof | RADIKAL THERAPEUTICS INC | 2016-01-27 | — | — | CN | disclosed |
| EP-2964218-A2 | PRODRUGS OF MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | Radikal Therapeutics Inc. (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20160002171-A1 | PRODRUGS OF MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | Salzman Group, Inc. | 2016-01-07 | — | — | US | disclosed |
| US-20140371267-A1 | OPHTHALMIC COMPOSITION WITH NITRIC OXIDE DONOR COMPOUND AND METHOD OF FORMING AND USING SAME | ALCON RESEARCH, LTD. (US) | 2014-12-18 | — | — | US | disclosed |
| WO-2014136059-A2 | PRODRUGS OF MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | RADIKAL THERAPEUTICS INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| US-20100197702-A1 | OPHTHALMIC COMPOSITION WITH NITRIC OXIDE DONOR COMPOUND AND METHOD OF FORMING AND USING SAME | ALCON RESEARCH, LTD. | 2010-08-05 | — | — | US | disclosed |
| US-20080149097-A1 | Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disordersB | YISSUM RESEARCH DEVELOPMENT COMPANY OF HEBREW UNIVERSITY OF JERUSALEM (IL) | 2008-06-26 | — | — | US | disclosed |
| US-7378438-B2 | Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2008-05-27 | — | — | US | disclosed |
| EP-1503754-B1 | BETA-AGONIST COMPOUNDS COMPRISING NITRIC OXIDE DONOR GROUPS AND REACTIVE OXYGEN SPECIES SCAVENGER GROUPS AND THEIR USE IN THE TREATMENT OF RESPIRATORY DISORDERS | YISSUM RES DEV CO (IL) | 2005-11-23 | — | — | EP | disclosed |
| US-20050228184-A1 | Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327466-A1 | METHOD FOR TREATING DISEASES ASSOCIATED WITH OXIDATIVE STRESS OR ENDOTHELIAL DYSFUNCTION | CYP11B1, CYP11B2, GPX4 | ADORA3 1677/4885ADORA1 1254/4885GAA 642/4885 |
| US-20160002171-A1 | PRODRUGS OF MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | NOS1, NOX1, NOS2 | ADORA3 1752/4885ADORA1 1275/4885GAA 919/4885 |
| US-20140371267-A1 | OPHTHALMIC COMPOSITION WITH NITRIC OXIDE DONOR COMPOUND AND METHOD OF FORMING AND USING SAME | NOS1, NOS3, NOS2 | ADORA3 130/4885ADORA1 89/4885GAA 4474/4885 |
| US-20080149097-A1 | Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disordersB | ADRA2B, ADRA1B, ADRB1 | ADORA3 62/4885ADORA1 58/4885GAA 2496/4885 |
| US-20100197702-A1 | OPHTHALMIC COMPOSITION WITH NITRIC OXIDE DONOR COMPOUND AND METHOD OF FORMING AND USING SAME | NOS1, NOS3, NOS2 | ADORA3 130/4885ADORA1 89/4885GAA 4474/4885 |
| US-20050228184-A1 | Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders | ADRB1, ADRB2, ADRB3 | ADORA3 49/4885ADORA1 54/4885GAA 2089/4885 |
| US-10000455-B2 | Method for treating diseases associated with oxidative stress or endothelial dysfunction using substituted 1-pyrrolidinyloxy, 1-piperidinyloxy and 1-azepanyloxy compounds | GPX1, LIPG, CYP11B1 | ADORA3 1838/4885ADORA1 763/4885GAA 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.